Portfolio Lab

Axogen, Inc.

  • Stock
  • Ticker AXGN
  • ISIN US05463X1063
  • Nasdaq

Health care · Medical technology · USA

$55.75 −1.06%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Axogen, Inc. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

AXGNGlobal equities (VT)

$10,000 grew to $65,205. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −93.5% in 11/2023, measured from the peak in 07/2018. It took 100 months to get back to the old peak.

1-year return
+117.2%
5-year return p.a.
+41.7%
10-year return p.a.
+20.6%
Volatility p.a.
61.3%
Largest decline
−93.5%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue4949576060617076
Gross profit3835424644465157
Operating income2.0-1.71.71.9-9.8-2.8-2.21.0
EBITDA3.70.13.33.6-8.1-1.2-0.52.5
Net income0.5-3.80.60.7-13-20-1.52.3
Earnings per share0.01-0.080.010.01-0.28-0.38-0.030.04
Balance sheet
Total assets204196205216222289305550
Liabilities10091939693454954
Equity104105112121129245256496
Cash28182024368395329
Long-term debt47484848480.00.00.0
Cash flow
Operating cash flow8.7-137.73.23.01.67.217
Capital expenditure-0.7-0.3-0.7-1.5-1.2-2.8-0.9-1.4
Free cash flow8.1-137.01.71.8-1.26.315

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2017 at +214.4%, weakest 2021 at −47.7%. 5 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
28 Oct 2026$0.04
29 Jul 2026−$0.03
28 Apr 2026−$0.38
24 Feb 2026−$0.28
29 Oct 2025$0.01
5 Aug 2025$0.01
8 May 2025−$0.08
26 Feb 2025$0.01
7 Nov 2024−$0.04
8 Aug 2024−$0.04
2 May 2024−$0.15
5 Mar 2024−$0.09

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€3.0bn
Market cap in trading currency
$3.33bn
Enterprise value
$2.98bn
P/E
–
P/S
12.48
P/B
6.71
EV/Sales
11.17
EV/EBITDA
–
Earnings yield
–
FCF yield
0.7%

Results (last four quarters)

Revenue
$267m
Gross profit
$198m
EBITDA
−$7.38m
Net income
−$31.9m
Earnings per share
−$0.65
Revenue per share
$4.47
Revenue growth
+26.2%
Earnings growth
+229.7%

Profitability

Gross margin
74.2%
Operating margin
-5.2%
Net margin
-12.0%
Return on equity
-10.3%
Return on assets
-5.8%

Balance sheet and cash flow

Cash
$348m
Cash per share
$5.83
Financial debt
$0
Debt/equity %
0
Current ratio
12.02
Book value per share
$8.31
Operating cash flow
$28.4m
Free cash flow
$22.0m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
–
Ex-dividend date
–

Shares and trading

Shares outstanding
59.7m
Volume
875,449
Avg. volume 3 months
1.57m
Relative volume
0.6

Price and technicals

Price
$55.75
1 day
−1.1%
52-week high
$58.63
52-week low
$25.67
Distance to 52-week high
−4.9%
Distance to 52-week low
+117.2%
Distance to 50-day line
+25.7%
Distance to 200-day line
+35.8%
RSI (14)
66
Volatility 1M
110.9%

Performance

1 week
−0.3%
1 month
+52.0%
3 months
+13.2%
6 months
+36.3%
YTD
+70.3%
1 year
+120.7%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has AXGN performed since 11/2016?

$10,000 grew to $65,205 by 20 Nov 2026, which is +20.6% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is AXGN?

Volatility was 61.3% per year, measured on monthly returns. The largest decline from a peak was −93.5%, with the low in 11/2023.

How does AXGN compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, AXGN returned +20.6% at 61.3%. The correlation of monthly returns was 0.24; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.